Target Price | $24.63 |
Price | $5.76 |
Potential |
327.52%
register free of charge
|
Number of Estimates | 8 |
8 Analysts have issued a price target Phathom Pharmaceuticals Inc 2026 .
The average Phathom Pharmaceuticals Inc target price is $24.63.
This is
327.52%
register free of charge
$28.00
386.11%
register free of charge
$17.00
195.14%
register free of charge
|
|
A rating was issued by 9 analysts: 8 Analysts recommend Phathom Pharmaceuticals Inc to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Phathom Pharmaceuticals Inc stock has an average upside potential 2026 of
327.52%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 0.68 | 50.50 |
7,326.21% | ||
EBITDA Margin | -24,520.59% | -493.95% |
97.99% | ||
Net Margin | -39,484.94% | -704.42% |
98.22% |
8 Analysts have issued a sales forecast Phathom Pharmaceuticals Inc 2024 . The average Phathom Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Phathom Pharmaceuticals Inc EBITDA forecast 2024. The average Phathom Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Phathom Pharmaceuticals Inc Analysts have issued a net profit forecast 2024. The average Phathom Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.93 | -5.21 |
22.18% | 32.57% | |
P/E | negative | |
EV/Sales | 11.45 |
3 Analysts have issued a Phathom Pharmaceuticals Inc forecast for earnings per share. The average Phathom Pharmaceuticals Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Phathom Pharmaceuticals Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Phathom Pharmaceuticals Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
Needham | Locked ➜ Locked | Locked | Jan 10 2025 |
HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 12 2024 |
Needham | Locked ➜ Locked | Locked | Dec 11 2024 |
Needham | Locked ➜ Locked | Locked | Sep 13 2024 |
Needham | Locked ➜ Locked | Locked | Sep 06 2024 |
Needham | Locked ➜ Locked | Locked | Aug 30 2024 |
Needham | Locked ➜ Locked | Locked | Aug 23 2024 |
Analyst Rating | Date |
---|---|
Locked
Needham: Locked ➜ Locked
|
Jan 10 2025 |
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 12 2024 |
Locked
Needham: Locked ➜ Locked
|
Dec 11 2024 |
Locked
Needham: Locked ➜ Locked
|
Sep 13 2024 |
Locked
Needham: Locked ➜ Locked
|
Sep 06 2024 |
Locked
Needham: Locked ➜ Locked
|
Aug 30 2024 |
Locked
Needham: Locked ➜ Locked
|
Aug 23 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.